REFERENCES
- Berthold F, Hero B, Kremens B, et al. Long-term results and risk profiles of patients in five consecutive trials (1979–1997) with stage 4 neuroblastoma over 1 year of age. Cancer Lett. 2003; 197(1–2)11–17
- Brodeur GM, Maris JM. Neuroblastoma. Lippincott Williams & Wilkins, Philadelphia 2006; 933–970
- Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999; 341: 1165–1173
- Stram DO, Matthay KK, O’Leary M, et al. Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies. J Clin Oncol. 1996; 14: 2417–2426
- Berthold F, Boos J, Burdach S, et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol. 2005; 6: 649–658
- Castel V, Tovar JA, Costa E, et al. The role of surgery in stage IV neuroblastoma. J Pediatr Surg. 2002; 37: 1574–1578
- Kaneko M, Ohakawa H, Iwakawa M. Is extensive surgery required for treatment of advanced neuroblastoma?. J Pediatr Surg. 1997; 32: 1616–1619
- Kushner BH, Wolden S, LaQuaglia MP, et al. Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery. J Clin Oncol. 2001; 19: 2821–2828
- Haas-Kogan DA, Swift PS, Selch M, et al. Impact of radiotherapy for high-risk neuroblastoma: a Children's Cancer Group study. Int J Radiat Oncol Biol Phys. 2003; 56: 28–39
- Bradfield SM, Douglas JG, Hawkins DS, et al. Fractionated low-dose radiotherapy after myeloablative stem cell transplantation for local control in patients with high-risk neuroblastoma. Cancer 2004; 100: 1268–1275
- Mugishima H, Matsunaga T, Yagi K, et al. Phase I study of irinotecan in pediatric patients with malignant solid tumors. J Pediatr Hematol Oncol. 2002; 24: 94–100
- Hara J, Osugi Y, Ohta H, et al. Double-conditioning regimens consisting of thiotepa, melphalan and busulfan with stem cell rescue for the treatment of pediatric solid tumors. Bone Marrow Transplant. 1998; 22: 7–12
- The Committee of Histological Classification of Childhood Tumors. Histrological Classfication and Color Atlas of Tumors inInfancy and Childhood: Peripheral Neuroblastic Tumors and Phenochromocytoma. Kanehara, Tokyo 2004; 34–35
- Kletzel M, Abella EM, Sandler ES, et al. Thiotepa and cyclophosphamide with stem cell rescue for consolidation therapy for children with high-risk neuroblastoma: a phase I/II study of the Pediatric Blood and Marrow Transplant Consortium. J Pediatr Hematol Oncol. 1998; 20: 49–54
- Pinkerton CR. ENSG 1-randomised study of high-dose melphalan in neuroblastoma. Bone Marrow Transplant. 1991; 7(Suppl 3)112–113